- The European Parliament urges the European Commission to boost the competitiveness of the European generic and biosimilar medicines industries and create additional jobs and growth in the EU.
- The export of generic and biosimilar medicines to unprotected markets during the SPC period will stimulate investments in Europe and help increase access to high quality medicines.
Medicines for Europe, the voice of the generic, biosimilar and added value medicine industries, applauds the adoption of the European Parliament’s report on the Single Market Strategy in Plenary. In their report, Members of the Parliament urged the European Commission to introduce and implement before 2019 an SPC (Supplementary Protection Certificate) manufacturing waiver to boost the competitiveness of the European generic and biosimilar medicines industries in a highly competitive global environment which will create additional jobs and growth in the EU.
The export of generic and biosimilar medicines to unprotected markets during the SPC period will stimulate investment in Europe, support the creation of highly skilled jobs and increase access to high quality medicines in third countries, without changing the equilibrium between the originator and the generic & biosimilar medicines industries in the EU.
“The European Parliament’s strong support for the creation of pharmaceutical manufacturing jobs in Europe through an SPC manufacturing waiver is clear” said Adrian van den Hoven, Medicines for Europe Director General. “This is the third time that the Parliament calls for the manufacturing waiver, now we expect the Commission to quickly introduce this strong trade stimulus to spur high-tech job creation and economic growth in Europe”.
For more information please follow us at www.medicinesforeurope.com and on Twitter @medicinesforEU.